CA2500772A1 - Uses of human zven antagonists - Google Patents

Uses of human zven antagonists Download PDF

Info

Publication number
CA2500772A1
CA2500772A1 CA002500772A CA2500772A CA2500772A1 CA 2500772 A1 CA2500772 A1 CA 2500772A1 CA 002500772 A CA002500772 A CA 002500772A CA 2500772 A CA2500772 A CA 2500772A CA 2500772 A1 CA2500772 A1 CA 2500772A1
Authority
CA
Canada
Prior art keywords
seq
zvenl
amino acid
zven2
zven
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002500772A
Other languages
English (en)
French (fr)
Inventor
Penny J. Thompson
Paul O. Sheppard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2500772A1 publication Critical patent/CA2500772A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
CA002500772A 2002-10-07 2003-10-07 Uses of human zven antagonists Abandoned CA2500772A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US41671902P 2002-10-07 2002-10-07
US41671802P 2002-10-07 2002-10-07
US60/416,719 2002-10-07
US60/416,718 2002-10-07
US43391802P 2002-12-16 2002-12-16
US43411602P 2002-12-16 2002-12-16
US60/433,918 2002-12-16
US60/434,116 2002-12-16
US50860303P 2003-10-03 2003-10-03
US50861403P 2003-10-03 2003-10-03
US60/508,603 2003-10-03
US60/508,614 2003-10-03
PCT/US2003/031562 WO2004032850A2 (en) 2002-10-07 2003-10-07 Uses of human zven antagonists

Publications (1)

Publication Number Publication Date
CA2500772A1 true CA2500772A1 (en) 2004-04-22

Family

ID=32097184

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002500772A Abandoned CA2500772A1 (en) 2002-10-07 2003-10-07 Uses of human zven antagonists
CA002500962A Abandoned CA2500962A1 (en) 2002-10-07 2003-10-07 Uses of human zven proteins and polynucleotides

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002500962A Abandoned CA2500962A1 (en) 2002-10-07 2003-10-07 Uses of human zven proteins and polynucleotides

Country Status (6)

Country Link
US (16) US7205110B2 (enExample)
EP (1) EP1558287A4 (enExample)
JP (1) JP2006514683A (enExample)
AU (2) AU2003279841A1 (enExample)
CA (2) CA2500772A1 (enExample)
WO (2) WO2004031367A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
ATE286136T1 (de) 1998-10-06 2005-01-15 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US6485938B1 (en) * 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
CA2500587A1 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Screening and therapeutic methods relating to neurogenesis
WO2004031367A2 (en) 2002-10-07 2004-04-15 Zymogenetics, Inc. Uses of human zven proteins and polynucleotides
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
CN101326168A (zh) 2005-03-24 2008-12-17 詹森药业有限公司 激肽原1受体拮抗剂
AU2006227394A1 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
EP2385042B1 (en) 2005-12-29 2015-11-25 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
WO2008121046A1 (en) * 2007-03-29 2008-10-09 Forskarpatent I Syd Ab Improvement of gastric emptying in patients suffering from diabetes mellitus
US20100286021A1 (en) * 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
US11650213B2 (en) * 2015-03-30 2023-05-16 Entvantage Diagnostics, Inc. Devices and assays for diagnosis of viral and bacterial infections

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756479A (en) * 1987-04-06 1988-07-12 Lazenby Iii George I Flush hydrant
US5294630A (en) * 1992-07-07 1994-03-15 Eli Lilly And Company Treatment of inflammatory bowel disease
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US5891720A (en) * 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
JP2001512013A (ja) 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP2002543840A (ja) * 1999-05-19 2002-12-24 インサイト・ゲノミックス・インコーポレイテッド 細胞外シグナル伝達分子
US6485938B1 (en) 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
AU1608201A (en) * 1999-11-16 2001-05-30 Zymogenetics Inc. Human zven proteins
EP1242454A2 (en) * 1999-12-28 2002-09-25 PHARMACIA & UPJOHN COMPANY G protein-coupled receptors
EP1302542B1 (en) * 2000-07-18 2007-06-13 Takeda Pharmaceutical Company Limited Novel physiologically active peptide and use thereof
WO2002036625A2 (en) * 2000-11-03 2002-05-10 The Regents Of The University Of California Prokineticin polypeptides, related compositions and methods
EP1506971A1 (en) * 2000-11-03 2005-02-16 The Regents of the University of California Prokineticin polypeptides, related compositions and methods
US6671555B2 (en) * 2001-04-27 2003-12-30 Medtronic, Inc. Closed loop neuromodulation for suppression of epileptic activity
AU2002359351A1 (en) 2001-11-02 2003-05-19 Nuvelo, Inc. Methods and materials relating to prokineticin-like polypeptides and polynucleotides
EP1581648A2 (en) * 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
WO2004031367A2 (en) 2002-10-07 2004-04-15 Zymogenetics, Inc. Uses of human zven proteins and polynucleotides
EP1589033A4 (en) 2003-01-22 2006-04-12 Takeda Pharmaceutical ANTIBODY AND ITS USE
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
WO2004087054A2 (en) * 2003-03-25 2004-10-14 The Regents Of The University Of California Methods for modulating gastric secretion using prokineticin receptor antagonists.
CA2543447A1 (en) 2003-10-22 2005-04-28 Takeda Pharmaceutical Company Limited Antibody and use of the same
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use

Also Published As

Publication number Publication date
AU2003295343A8 (en) 2004-04-23
WO2004031367A2 (en) 2004-04-15
CA2500962A1 (en) 2004-04-15
US20090312258A1 (en) 2009-12-17
US20070048258A1 (en) 2007-03-01
US20040156842A1 (en) 2004-08-12
US20070065405A1 (en) 2007-03-22
US7531311B2 (en) 2009-05-12
US7205110B2 (en) 2007-04-17
WO2004031367A3 (en) 2004-07-22
US20070065404A1 (en) 2007-03-22
US7291589B2 (en) 2007-11-06
US20070092912A1 (en) 2007-04-26
US20070053908A1 (en) 2007-03-08
WO2004032850A2 (en) 2004-04-22
US20090312257A1 (en) 2009-12-17
US20070048778A1 (en) 2007-03-01
US20070053907A1 (en) 2007-03-08
US20040162238A1 (en) 2004-08-19
US20070087414A1 (en) 2007-04-19
US7629445B2 (en) 2009-12-08
US20070065403A1 (en) 2007-03-22
AU2003279841A1 (en) 2004-05-04
US20070049526A1 (en) 2007-03-01
JP2006514683A (ja) 2006-05-11
AU2003295343A1 (en) 2004-04-23
EP1558287A4 (en) 2009-07-08
WO2004032850A3 (en) 2005-03-17
US7592312B2 (en) 2009-09-22
US20090312256A1 (en) 2009-12-17
EP1558287A2 (en) 2005-08-03
US20070078259A1 (en) 2007-04-05
AU2003279841A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
US20090312258A1 (en) Uses of human zven proteins and polynucleotides
US6828425B2 (en) Antibodies that bind human Zven1
US20060258586A1 (en) Compositions and uses of secreted polypeptide, Zsig98
CA2392128A1 (en) Human zven proteins
EP1551440A2 (en) Uses of human zven proteins and polynucleotides
JP2006515989A (ja) ヒトｚｖｅｎタンパク質及びポリヌクレオチドの使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued